基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究

doi:10.11904/j.issn.1002-3070.2022.06.009

摘要/Abstract

摘要： 目的在真实世界中探索晚期食管鳞癌(Esophageal squamous cell carcinoma,ESCC)患者一线应用免疫检查点抑制剂联合标准化疗对比单纯标准化疗之间的疗效和安全性差异以及预后相关因素。方法回顾性分析2018年1月—2020年12月在哈尔滨医科大学附属肿瘤医院就诊的未经过系统治疗的107例局部晚期或转移性ESCC患者的临床资料。根据其一线治疗方案分为应用程序性细胞死亡蛋白-1(Programmed cell death-1,PD-1)抑制剂联合化疗组(联合化疗组)和单纯标准化疗组(单纯化疗组),比较两组的无进展生存期(Progression-free survival,PFS)、客观缓解率(Objective response rate,ORR)、疾病控制率(Disease control rate,DCR)以及治疗相关不良反应(Treatment-related adverse events,TRAEs)发生情况,并且寻找与晚期ESCC患者PFS相关的影响因素。结果共收集107例(联合化疗组56例,单纯化疗组51例)患者资料,经倾向评分匹配(Propensity score matching,PSM)后获得联合化疗组和单纯化疗组各31例。联合化疗组对比单纯化疗组的ORR差异无统计学意义(38.7% vs. 19.4%,P＞0.05);DCR差异无统计学意义(96.8% vs. 90.3%,P＞0.05);两组PFS差异具有统计学意义(中位PFS:11.87个月 vs. 7.7个月,P=0.001)。Cox回归分析显示是否使用PD-1抑制剂以及病灶位置是PFS的独立影响因素。联合化疗组和单纯化疗组TRAEs发生率分别为80.6%和67.7%,联合化疗组中有5例(16.1%)发生免疫相关不良事件(immune-related adverse events,irAEs),以上不良反应可耐受或经药物治疗后缓解,未影响化疗药物的使用。结论在真实世界临床中,晚期ESCC患者一线应用免疫检查点抑制剂联合标准化疗的疗效优于单纯标准化疗。未观察到免疫治疗相关不良反应导致的停药。ESCC病灶位置位于上中段的患者预后优于病灶位于下段的患者。

关键词: 晚期食管鳞癌, 免疫检查点抑制剂, 化疗, 疗效, 预测因素

Abstract: Objective The aim of this study was to explore the efficacy,safety difference and prognostic factors between first-line immune checkpoint inhibitor combined with standard chemotherapy and standard chemotherapy alone in patients with advanced esophageal squamous cell carcinoma(ESCC)in the real world.Methods The clinical data of 107 patients with locally advanced or metastatic ESCC who were treated in our hospital from January 2018 to December 2020 were retrospectively analyzed.According to their first-line treatment schemes,they were divided into the application of programmed cell death protein-1(PD-1)inhibitors combined standard chemotherapy group and the standard chemotherapy group alone.The progression free survival(PFS),Objective response rate(ORR),disease control rate(DCR)and the occurrence of treatment-related adverse events(TRAEs)were compared between of the two groups and influencing factors related to PFS in patients with advanced ESCC were analyzed.Results A total of 107 patients(56 in the combined treatment group and 51 in the chemotherapy group)were collected.After propensity score matching(PSM),31 patients in the combined treatment group and 31 patients in the chemotherapy group were obtained.There was no significant difference in ORR between the combined chemotherapy group and the chemotherapy alone group(38.7% vs. 19.4%,P＞0.05);the difference in DCR was not statistically significant(96.8% vs. 90.3%,P＞ 0.05);the difference in PFS was statistically significant(median PFS:11.87 months vs. 7.7 months,P=0.001).Cox regression analysis showed that use of PD-1 inhibitors and the location of lesions were independent influencing factors of PFS.The incidence of TRAEs in the combined chemotherapy group and chemotherapy alone group were 80.6% and 67.7%,respectively,and 5 cases(16.1%)in the combined chemotherapy group had immune-related adverse events(irAEs),and the above adverse reactions were tolerable or relieved after drug treatment,without affecting the use of chemotherapy drugs.Conclusion In the real world clinical practice,the efficacy of first-line immune checkpoint inhibitor combined with standard chemotherapy in patients with advanced ESCC is better than that of standard chemotherapy alone.No discontinuation due to immunotherapy-related adverse reactions was observed.The prognosis of patients with ESCC lesions located in the upper and middle segments is better than that of patients with ESCC lesions located in the lower segment.

Key words: Advanced esophageal squamous cell carcinoma, Immune checkpoint inhibitor, Chemotherapy, Efficacy, Predictive factors

中图分类号:

R735.1

杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.

YANG Lei, ZHANG Zhengfeng, WANG Dazhen, LOU Changjie. Real-world retrospective controlled study of first-line standard chemotherapy combined with immune checkpoint inhibitor versus standard chemotherapy for advanced esophageal squamous cell carcinoma[J]. Journal of Practical Oncology, 2022, 36(6): 538-543.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/538

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Xia CF,Dong XS,Li H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J(Engl),2022,135(5):584-590.
3 Tarazi M,Chidambaram S,Markar SR.Risk factors of esophageal squamous cell carcinoma beyond alcohol and smoking[J].Cancers(Basel),2021,13(5):1009.
4 Miller KD,Siegel RL,Lin CC,et al.Cancer treatment and survivorship statistics,2016[J].CA Cancer J Clin,2016,66(4):271-289.
5 Akinleye A,Rasool Z.Immune checkpoint inhibitors of PD-L1 as cancer therapeutics[J].Hematol Oncol,2019,12(1):92.
6 张喻,曲艺,董丽,等.真实世界证据与随机对照试验证据比较研究[J].中国新药杂志,2021,30(11):971-975.
7 Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45:228-247.
8 Buchbinder EI.Immune checkpoint therapies for melanoma[J].Hematol Oncol Clin North Am,2021,35(1):99-109.
9 Finn RS,Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894-1905.
10 李瑞阳,方琳,张艳桥.食管癌免疫治疗研究进展[J].实用肿瘤学杂志,2021,35(1):41-45.
11 Sun JM,Shen L,Shah MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised,placebo-controlled,phase 3 study[J].Lancet,2021,398(10302):759-771.
12 Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):A randomised,open-label,phase 3 trial[J].Lancet,2021,398(10294):27-40.
13 Luo HY,Lu J,Bai YX,et al.Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma:the ESCORT-1st randomized clinical trial[J].JAMA,2021,326(10):916-925.
14 Megan G,Joanne FC,Walid KC,et al.Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer[J].Clin Cancer Res,2019,25(20):6160-6169.
15 Avis AA,Patel VG.The role of PD-L1 expression as a predictive biomarker:An analysis of all US Food and Drug Administration(FDA)approvals of immune checkpoint inhibitors[J].J Immunother Cancer,2019,7(1):278.
16 Ghosh C,Luong G,Sun Y.A snapshot of the PD-1/PD-L1 pathway[J].J Cancer,2021,12(9):2735-2746.
17 Cho YA,Lee H,Kim DG,et al.PD-L1 expression is significantly associated with tumor mutation burden and microsatellite instability score[J].Cancers,2021,13(18):4659.
18 Le DT,Durham JN,Smith KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J].Science,2017,357(6349):409-413.
19 Yarchoan M,Hopkins A,Jaffee EM,et al.Tumor mutational burden and response rate to PD-1 inhibition[J].N Engl J Med,2017,377(25):2500-2501.
20 Chalmers ZR,Connelly CF,Fabrizio D,et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden[J].Genome Med,2017,9(1):34.
21 Hatogai K,Fujii S,Kitano S,et al.Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma[J].Br J Cancer,2020,122(3):413-420.
22 Chen PL,Roh W,Reuben A,et al.Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade[J].Cancer Discov,2016,6(8):827-837.
23 Zhou S,Yang H,Zhang J,et al.Changes in indoleamine 2,3-dioxygenase 1 expression and CD8+ tumor-infiltrating lymphocytes after neoadjuvant chemoradiotherapy and prognostic significance in esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2020,108(1):286-294.

[1]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[2]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[3]	康子曼, 杨聃琳, 孙建男. 乳腺MRI图像纹理分析在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 472-476.
[4]	连晓敏, 马峰, 赵丽霞, 孟玮, 赵丹丹, 赵峻峰. PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析[J]. 实用肿瘤学杂志, 2022, 36(4): 339-345.
[5]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[6]	梁洁, 王新华, 王健, 夏欢. 非远处转移性甲状腺乳头状癌¹³¹I疗效预测模型的分析[J]. 实用肿瘤学杂志, 2022, 36(3): 220-225.
[7]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[8]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[9]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[10]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.
[11]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[12]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[13]	张文静, 刘金爽, 王丹, 黎清炜, 李志伟. 胰腺癌新辅助治疗的研究现状[J]. 实用肿瘤学杂志, 2022, 36(1): 64-68.
[14]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[15]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.